We are live on
!
Find out more
DP
Diadema Partners Portfolio holdings
AUM
$588M
1-Year Est. Return
182.75%
This Fund
S&P 500
This Quarter
Est. Return
+9.46%
1 Year Est. Return
+182.75%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$233M
AUM Growth
–
Cap. Flow
+$273M
Cap. Flow
% of AUM
117.2%
Top 10 Holdings %
Top 10 Hldgs %
44.5%
Holding
107
New
107
Increased
–
Reduced
–
Closed
–
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
AbbVie
ABBV
|
+$9.19M |
| 2 |
Bristol-Myers Squibb
BMY
|
+$8.94M |
| 3 |
ONC
BeOne Medicines Ltd
ONC
|
+$6.13M |
| 4 |
BPMC
Blueprint Medicines
BPMC
|
+$5.88M |
| 5 |
Teva Pharmaceuticals
TEVA
|
+$5.46M |
Top Sells
No sells this quarter
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 38.08% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
CALL
Vertex Pharmaceuticals
VRTX
$121B
| $23.1M | 9.92% |
+57,400
| New | +$26.6M |
|
2
PUT
State Street SPDR S&P Biotech ETF
XBI
$9.95B
| $18M | 7.73% |
+200,000
| New | +$19.4M |
|
|
3
Bristol-Myers Squibb
BMY
$133B
| $9.05M | 3.88% |
+160,000
| New | +$8.94M |
|
|
4
AbbVie
ABBV
$443B
| $8.88M | 3.81% |
+50,000
| New | +$9.19M |
|
|
5
PUT
AbbVie
ABBV
$443B
| $8.88M | 3.81% |
+50,000
| New | +$9.19M |
|
|
SLNO
6
PUT
DELISTED
Soleno Therapeutics
SLNO
| $7.88M | 3.38% |
+175,400
| New | +$9.09M |
|
|
ACLX
7
PUT
DELISTED
Arcellx
ACLX
| $7.67M | 3.29% |
+100,000
| New | +$8.64M |
|
8
CALL
CRISPR Therapeutics
CRSP
$4.73B
| $7.51M | 3.22% |
+190,800
| New | +$9.01M |
|
|
9
Teva Pharmaceuticals
TEVA
$40.8B
| $6.68M | 2.86% |
+300,000
| New | +$5.46M |
|
10
PUT
TG Therapeutics
TGTX
$7.96B
| $6.02M | 2.58% |
+200,000
| New | +$5.74M |
|
|
BPMC
11
DELISTED
Blueprint Medicines
BPMC
| $5.6M | 2.4% |
+64,193
| New | +$5.88M |
|
12
CALL
Halozyme
HALO
$9.79B
| $4.78M | 2.05% |
+100,000
| New | +$5.13M |
|
13
PUT
Ultragenyx Pharmaceutical
RARE
$2.45B
| $4.44M | 1.9% |
+105,500
| New | +$5.23M |
|
|
SLNO
14
CALL
DELISTED
Soleno Therapeutics
SLNO
| $4.25M | 1.82% |
+94,600
| New | +$4.9M |
|
15
Rhythm Pharmaceuticals
RYTM
$6.81B
| $4.2M | 1.8% |
+75,000
| New | +$4.14M |
|
16
AstraZeneca
AZN
$263B
| $3.93M | 1.69% |
+15,000
| New | +$2.1M |
|
17
Insmed
INSM
$21.4B
| $3.89M | 1.67% |
+56,337
| New | +$4.06M |
|
18
CALL
Biohaven
BHVN
$2.03B
| $3.73M | 1.6% |
+100,000
| New | +$4.67M |
|
|
ITCI
19
CALL
DELISTED
Intra-Cellular Therapies Inc.
ITCI
| $3.65M | 1.57% |
+43,700
| New | +$3.59M |
|
20
Ascendis Pharma A/S
ASND
$16B
| $3.48M | 1.49% |
+25,276
| New | +$3.32M |
|
|
21
CALL
Insmed
INSM
$21.4B
| $3.45M | 1.48% |
+50,000
| New | +$3.6M |
|
22
CALL
Agios Pharmaceuticals
AGIO
$1.79B
| $3.35M | 1.44% |
+102,000
| New | +$4.79M |
|
23
Tarsus Pharmaceuticals
TARS
$2.58B
| $3.32M | 1.43% |
+60,000
| New | +$2.73M |
|
|
SLNO
24
DELISTED
Soleno Therapeutics
SLNO
| $3.24M | 1.39% |
+71,988
| New | +$3.73M |
|
|
APLS
25
CALL
DELISTED
Apellis Pharmaceuticals
APLS
| $3.19M | 1.37% |
+100,000
| New | +$3.01M |
|
Similar funds
MC
PFG
FMI
EGWAG
PFG
GIM
FL
BA
Diadema Partners's Q4 2024 Portfolio in Review
Q4 2024 is the first quarter with a 13F filing on record for Diadema Partners, which disclosed 107 positions worth $233M. Its ten largest holdings account for 44% of the portfolio.
Its largest position is AbbVie: 50,000 shares worth $8.88M.
By sector, the portfolio is most concentrated in Healthcare at 38% of assets.
- Diadema Partners's largest Q4 2024 buy was AbbVie: 50,000 shares worth $8.88M.
- Diadema Partners's ten largest holdings make up 44% of its $233M portfolio in Q4 2024.
- Diadema Partners disclosed 107 positions in Q4 2024, its first 13F filing on record.
Based on Diadema Partners's 13F filing for Q4 2024, filed 14 Feb 2025.